Hepatobiliary cancers clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 8, 2006, Pages 728-750

  Benson III, Al B ^a   Bekaii Saab, Tanios ^b   Ben Josef, Edgar ^c   Blumgart, Leslie ^d   Clary, Bryan M ^e   Curley, Steven A ^f   Davila, Rene ^g   Earle, Craig C ^h   Ensminger, William D ^c   Gibbs, John F ⁱ   Laheru, Daniel ^j   Langnas, Alan N ^k   Mulvihill, Sean J ^l   Nemcek Jr , Albert A ^a   Posey, James A ^m   Sigurdson, Elin R ⁿ   Sinanan, Mika ^o   Vauthey, Jean Nicolas ^f   Venook, Alan P ^p   Wagman, Lawrence D ^q   Yeatman, Timothy J ^r   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^h Dana Farber/Partners CancerCare   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ FOX CHASE CANCER CENTER   (United States)

^o SEATTLE CANCER CARE ALLIANCE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q City of Hope Cancer Center   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

Chemoembolization; Cholangiocarcinomas; Cirrhosis; Gallbladder cancer; Hepatitis C; Hepatocellular carcinoma; NCCN Clinical Practice Guidelines; Surgical resection; Transplantation; Tumor ablation

Indexed keywords

AFLATOXIN B1; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ANTIVIRUS AGENT; CARCINOGEN; FLUOROURACIL; GEMCITABINE; INTERFERON; MITOMYCIN;

ADJUVANT CHEMOTHERAPY; BILE DUCT CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; GALLBLADDER CANCER; HEPATITIS C; HEPATOBILIARY SYSTEM CANCER; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SCORING SYSTEM;

EID: 33748766060     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0064     Document Type: Review

References (80)

1. Pawlik TM, Scoggins CR, Thomas MB, er al. Advances in the surgical management of liver malignancies. Cancer J 2004;10;74-87.
2. de Groen P, Gores G, LaRusso N, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
4. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-1427.
5. Okuda K, Odata H, Nakajina Y, et al. Prognosis of primary hepatocellular cancer. Hepatology 1984;4:3.
6. Colombo M. Hepatocellular carcinoma. J Hepatol 1992;15:225-236.
7. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823
8. (erratum in: Ann Intern Med 2004;140:151).
9. Cusnir M, Patt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004;10:97-103.
10. Izzo F, Cremona F, Ruffolo F, et al. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg 1998;227:513-518.
11. Kim W, Oe Lim S, Kim JS, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 2003;9:5493-5500.
12. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for heparocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. J Cancer 1999;81:695-699.
13. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1567.
14. Shafritz DA. Synthetic retinoids for the secondary prevention of hepatocellular carcinoma. N Engl J Med 1996;334:1600-1601.
15. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-985.
16. Fung KT, Li FT, Raimondo ML, et al. Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol 2004;77:633-640.
17. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-1864.
18. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
19. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.
20. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BLCL staging classification. Semin Liver Dis 1999;19:329-338.
21. The Cancer of the Liver Italian Program (CLIP) Investigators: prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-845.
22. Falkson G, Cnaan A, Schutt AJ, et al. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988;48:7314-7318.
23. Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331:1547-1552.
24. Farmer DG, Busuttil RW. The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer 1994;73:2669-2670.
25. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323-1334.
26. Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003;238:315-321; discussion 321-323.
27. Ueno S, Tanabe G, Nuruki K, et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg 2002;9:469-477.
28. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022.
29. Wakabayashi H, Okada S, Maeba T, et al. Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: a preliminary report. Surg Today 1997;27:403-410.
30. Esnaola NF, Mirza N, Lauwers GY, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 2003;238:711-719.
31. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004;10:S46-S52.
32. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
33. Madoff DC, Hicks ME, Abdalla EK, et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepacobiliary malignancy: safety and effectiveness-study in 26 patients. Radiology 2003;227:251-260.
34. Regalia E, Coppa J, Pulvirenti A, et al. Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. Transplant Proc 2001;33:1442-1444.
35. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
36. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
37. Kanwal F, Dulai GS, Spiegel BM, et al. A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras. Aliment Pharmacol Ther 2005;21:169-177.
38. Roayaie S, Frischet JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-539.
39. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130-1137.
40. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003;238:508-518.
41. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239:142-149.
42. Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003;226:441-451.
43. Mazzanti R, Arena U, Pantaleo P, et al. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. Can J Gastroenterol 2004;18:611-618.
44. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-1868.
45. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005;234:954-960.
46. Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990;8:1108-1114.
47. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis of the Cox proportional hazard model. Cancer 1991;68:2150-2154.
48. Yamashita Y, Takahasi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;67:385-391.
49. Raoul JL, Heresbach D, Bretagne, et al. Chemoembolization of hepatocellular carcinomas. Cancer 1992;70:585-590.
50. Taguchi T, Nakamura H. Chemoembolization therapy for hepatocellular carcinoma injapan. J Infus Chemother 1992;2:124-127.
51. Lyster MT, Benson AB, Vogelzang R, et al. Chemoembolization: alternative for hepatic tumors. Contemp Oncol 1993;3:17-28.
52. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. Cancer 1994;74:16-24.
53. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol Chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
54. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1294-1296.
55. Alexander HR, Bartlett DL, Fraker DL, et al. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. PPO Updates: Principles and Practice of Oncology 1996;10:1-19.
56. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996;77:1792-1796.
57. Dawson L, McOinn C, Normolle D, et al. Escalated focal liver radiation and hepatic artery floxuridine for unresectable liver malignancies. J Clin Oncol 2000;18:2210-2218.
58. Jones RS. Carcinoma of the gallbladder. Surg Oncol Clin North Am 1990;70:1419.
59. Nakeeb A, Put HA. The role of preoperative biliary decompression in obstructive jaundice. Hepatogastroenterology 1995;42:332.
60. Fong Y. Aggressive therapy is warranted for gallbladder cancer. Cancer Invest 1998;16:64.
61. Maibenco DC, Smith JL, Nava HR, et al. Carcinoma of the gallbladder. Cancer Invest 1998;16:33.
62. Rajagopalan V, Daines WP, Grossbard ML, et al. Gallbladder and biliary tract carcinoma: a comprehensive update, Part 1. Oncology 2004;18:889-896.
63. Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:167-175.
64. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695.
65. Daines WP, Rajagopalan V, Grossbard ML, et al. Gallbladder and biliary tract carcinoma: a comprehensive update, Part 2. Oncology (Williston Park) 2004;18:1049-1059.
66. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578-586.
67. Vogt DP. Current management of cholangiocarcinoma. Oncology 1988;2:37-43.
68. Altaee MY, Johnson PJ, Farrant JM, et al. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991;68:2051-2055.
69. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of the biliary tree. Curr Probl Surg 1995;32:1.
70. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517; discussion 517-519.
71. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170-178.
72. Kubicka S, Rudolph K, Tietze M, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;39:783-789.
73. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774-779.
74. Heimbach JK, Haddock MG, Alberts SR, et al. Transplantation for hilar cholangiocarcinoma. Liver Transpl 2004;10:S65-S68.
75. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-608.
76. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.
77. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopie drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:1-7.
78. Schiefke I, Zabel-Langhennig A, Wiedmann M, et al. Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc 2003;58:213-219.
79. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-1120.
80. Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004;60:68-75.